Literature DB >> 21951032

The effect of topical vancomycin applied to sternotomy incisions on postoperative serum vancomycin levels.

Harold L Lazar1, Tamar Barlam, Howard Cabral.   

Abstract

BACKGROUND AND AIM: Topical vancomycin has been shown to reduce the incidence of sternal wound infections but concerns have been raised that persistent serum levels of vancomycin may contribute to the emergence of drug-resistant infections. This study was undertaken to determine: (1) whether serum levels of vancomycin remain elevated when applied topically to the sternum and (2) whether the use of topical vancomycin can potentiate postoperative drug-resistant infections.
METHODS: Serum vancomycin levels were measured on the evening of surgery and the sixth postoperative day in 36 patients in which topical vancomycin was applied to the cut edges of the sternum during their cardiac surgical procedures. Data are presented as a mean ± standard deviation and statistical significance was tested using paired t-test analyses.
RESULTS: There was a significant decrease in serum vancomycin levels from the night of surgery to the sixth postoperative day (11.5 ± 1.9 μg/mL to 2.12 ± 0.79 μg/mL; p <0.0001). The incidence of sternal infections was 0% and no patient developed any infection or had renal toxicity during the 12-month follow-up.
CONCLUSIONS: The use of topical vancomycin applied to the sternotomy incision does not result in persistently elevated levels of serum vancomycin following cardiac surgical procedures. Furthermore, topical vancomycin does not potentiate the emergence of drug-resistant infections or contribute to postoperative renal toxicity.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951032     DOI: 10.1111/j.1540-8191.2011.01300.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  7 in total

Review 1.  The successful use of vancomycin-impregnated cement beads in a patient with vancomycin systemic toxicity: a case report with review of literature.

Authors:  V Mounasamy; P Fulco; P Desai; R Adelaar; G Bearman
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-08-08

2.  Topical spraying of cefazolin and gentamicin reduces deep sternal wound infections after heart surgery: a multicenter, large volume, retrospective study.

Authors:  Hiroshi Osawa; Shinpei Yoshii; Samuel J K Abraham; Yuki Okamoto; Shigeru Hosaka; Shoji Fukuda; Koji Tsuchiya; Masato Nakajima; Yoshihiro Honda; Kouki Takizawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-12-31

3.  A review of the AATS guidelines for the prevention and management of sternal wound infections.

Authors:  Harold L Lazar
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2018-07-17

4.  Computed Tomography Imaging Assessment of the Effect of Vancomycin Paste on Poststernotomy Healing.

Authors:  Mohammad Abd Alkhalik Basha; Dina Said Shemais; Essam Saad Abdelwahed; Rabab Mahmoud Elfwakhry; Ayman Fathy Zeid; Ahmed A El-Hamid M Abdalla; Sameh Abdelaziz Aly; Dalia Said Abdelrahman; Anwar A Elshenawy; Waleed Mansour; Khaled Ahmed Ahmed Elbanna; Mohammad El Tahlawi; Nezar Elnahal
Journal:  Int J Gen Med       Date:  2021-12-02

5.  Commentary on: "Sterile Seroma Resulting from Multilevel XLIF Procedure as Possible Adverse Effect of Prophylactic Vancomycin Powder: A Case Report".

Authors:  Scott L Parker; Clinton J Devin
Journal:  Evid Based Spine Care J       Date:  2014-10

6.  Vancomycin Wrap for Anterior Cruciate Ligament Surgery: Molecular Insights.

Authors:  Caroline M Atherton; Simon J Spencer; Katy McCall; Emma Garcia-Melchor; William J Leach; Michael Mullen; Brian P Rooney; Colin Walker; Iain B McInnes; Neal L Millar; Moeed Akbar
Journal:  Am J Sports Med       Date:  2021-01-06       Impact factor: 6.202

7.  Surgical treatment and long-term outcome of aortic valve endocarditis with periannular abscess.

Authors:  S I Croon; A Angkasuwan; A H van Straten; A Khamooshian; T W Elenbaas; M A Soliman-Hamad
Journal:  Neth Heart J       Date:  2020-06       Impact factor: 2.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.